524394 Stock Overview
Vimta Labs Limited provides contract research and testing services in India and internationally.
Vimta Labs Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹344.80|
|52 Week High||₹453.00|
|52 Week Low||₹216.00|
|1 Month Change||-9.00%|
|3 Month Change||2.90%|
|1 Year Change||58.42%|
|3 Year Change||76.14%|
|5 Year Change||189.87%|
|Change since IPO||31,245.46%|
Recent News & Updates
|524394||IN Life Sciences||IN Market|
Return vs Industry: 524394 exceeded the Indian Life Sciences industry which returned 3.1% over the past year.
Return vs Market: 524394 exceeded the Indian Market which returned 9.5% over the past year.
|524394 Average Weekly Movement||7.0%|
|Life Sciences Industry Average Movement||7.1%|
|Market Average Movement||7.2%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.8%|
Stable Share Price: 524394 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 524394's weekly volatility (7%) has been stable over the past year.
About the Company
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. It serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries.
Vimta Labs Fundamentals Summary
|524394 fundamental statistics|
Is 524394 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|524394 income statement (TTM)|
|Cost of Revenue||₹791.96m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||18.69|
|Net Profit Margin||14.85%|
How did 524394 perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is Vimta Labs undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 524394 (₹344.8) is trading below our estimate of fair value (₹608.78)
Significantly Below Fair Value: 524394 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian Life Sciences industry average (34.9x).
PE vs Market: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian market (20.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524394's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524394 is overvalued based on its PB Ratio (3.3x) compared to the IN Life Sciences industry average (2.9x).
How is Vimta Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vimta Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Vimta Labs performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524394 has high quality earnings.
Growing Profit Margin: 524394's current net profit margins (14.9%) are higher than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: 524394's earnings have grown by 19.3% per year over the past 5 years.
Accelerating Growth: 524394's earnings growth over the past year (93.1%) exceeds its 5-year average (19.3% per year).
Earnings vs Industry: 524394 earnings growth over the past year (93.1%) exceeded the Life Sciences industry 37.3%.
Return on Equity
High ROE: 524394's Return on Equity (17.7%) is considered low.
How is Vimta Labs's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 524394's short term assets (₹1.2B) exceed its short term liabilities (₹477.5M).
Long Term Liabilities: 524394's short term assets (₹1.2B) exceed its long term liabilities (₹254.7M).
Debt to Equity History and Analysis
Debt Level: 524394's net debt to equity ratio (3.4%) is considered satisfactory.
Reducing Debt: 524394's debt to equity ratio has reduced from 32% to 8.3% over the past 5 years.
Debt Coverage: 524394's debt is well covered by operating cash flow (305.4%).
Interest Coverage: 524394's interest payments on its debt are well covered by EBIT (38x coverage).
What is Vimta Labs's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 524394's dividend (0.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: 524394's dividend (0.58%) is low compared to the top 25% of dividend payers in the Indian market (1.6%).
Stability and Growth of Payments
Stable Dividend: 524394's dividend payments have been volatile in the past 10 years.
Growing Dividend: 524394's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (10.7%), 524394's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (21.7%), 524394's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Harita Vasireddi (47 yo)
Ms. Harita Vasireddi, B. Pharm, MBA (USA) has been the Managing Director of Vimta Labs Ltd. since July 15, 2013 and serves as its Whole Time Director. She was a Member of Scientific Advisory Board at Vimta...
CEO Compensation Analysis
Compensation vs Market: Harita's total compensation ($USD86.36K) is above average for companies of similar size in the Indian market ($USD38.56K).
Compensation vs Earnings: Harita's compensation has been consistent with company performance over the past year.
Experienced Management: 524394's management team is seasoned and experienced (5 years average tenure).
Experienced Board: 524394's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vimta Labs Limited's employee growth, exchange listings and data sources
- Name: Vimta Labs Limited
- Ticker: 524394
- Exchange: BSE
- Founded: 1984
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹7.623b
- Shares outstanding: 22.11m
- Website: https://www.vimta.com
Number of Employees
- Vimta Labs Limited
- Plot Nos. 141/2 & 142, IDA, Phase II
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.